FDA daily for Thursday, September 10, 2026
In this issue: 1 shortage update and 7 approvals. 1 item touches categories MedGrid carries, and it comes first.
For MedGrid's categories
Items in this issue that name a product category sold on MedGrid. Each links to its full FDA record; the chip opens that category's federal and state rules.
- TESTOSTERONE CYPIONATE
BPI LABS · TESTOSTERONE CYPIONATE
Drug shortages
FDA date:FDA updated 1 shortage entry on Wed, Sep 9: 1 new, 1 to be discontinued.
- Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection
Merck Sharp & Dohme LLC
Drug and biologic approvals
FDA date:On Thu, Sep 3 FDA approved 5 new applications (2 brand or biologic, 3 generic) and 2 supplements to existing ones.
- TESTOSTERONE CYPIONATE
BPI LABS · TESTOSTERONE CYPIONATE
- MODAFINIL
LUPIN · MODAFINIL
- OMCAZIO
HANDA ONCOL · CABOZANTINIB LAURYLSULFATE
- TAPENTADOL HYDROCHLORIDE
MSN · TAPENTADOL HYDROCHLORIDE
- ZANVASTRO
IONIS PHARMS INC · ZILGANERSEN SODIUM
FDA did not answer for Drug recalls, Food and supplement recalls, Clearances, Labels, Device recalls while this issue was written; those sections will fill in on a later visit.
How the FDA daily is written
Every issue is written from FDA's public data (openFDA) and nothing else: the counts, names, firms and reasons are FDA's own. openFDA posts each kind of record on its own delay, so each section covers one FDA date and says which. Shortages cover yesterday; approvals, drug and device recalls, and food and supplement recalls cover a week ago; device clearances and label changes cover two weeks ago. Every FDA date appears in exactly one issue. Complete response letters appear the day after FDA publishes a batch.
Subscribe with any feed reader, or point an email tool at the RSS feed to send each issue as a newsletter. Search any drug, device or company across every FDA dataset in the FDA data explorer.
